iTeos Therapeutics Awarded EUR 3 Million in Funding a New Drug Discovery Program for Cancer Immunotherapy

Share Article

Walloon Government supports the development of iTeos proprietary pipeline to develop novel therapeutics targeting the immune tumor micro-environment

News Image

iTeos Therapeutics SA, the drug discovery company for immunomodulators, announced that it has received a €2.94 million non-dilutive funding from the Walloon Region of Belgium to expand its preclinical drug discovery pipeline targeting new immunotherapies for the tumor micro-environment.

“This grant will allow us to expand our proprietary pipeline by adding a program to develop small molecule inhibitors for a target involved in T cell anergy”. said Christophe Quéva Ph.D., chief scientific officer of iTeos. “It will complement our growing portfolio of small molecules and antibody approaches aimed at stimulating certain immune responses against cancers.”

"We are very pleased to continue to receive strong support for our preclinical research from the Walloon Region. In parallel to our strategic collaboration with Pfizer, which was announced in 2014, we are expanding the Company’s drug candidate pipeline where such grant support is pivotal for our research efforts to discover our own diversified and innovative set of drug candidate programs." said Michel Detheux Ph.D., chief executive officer of iTeos.

About iTeos Therapeutics SA
Based in Gosselies, Belgium, iTeos, a spin-off of Ludwig Cancer Research (LICR) and de Duve Institute (UCL), has built a discovery platform to identify therapeutics targeting the immune tumor micro-environment to optimize cancer immunotherapy. iTeos combines unparalleled expertise in tumor immunology, cancer immunotherapy and drug discovery. The company entered into a strategic collaboration with Pfizer in December 2014. iTeos is developing partnerships with charities, top-tier academic and industrial partners to develop new programs. iTeos is supported by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Alfred Gray
Visit website